OXALIEVA 100MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | OXALIEVA 100MG |
|---|---|
| Composition | Oxaliplatin Injection USP 100mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
OXALIEVA 100MG (Oxaliplatin Injection USP 100mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
OXALIEVA 100 MG (Oxaliplatin Injection USP 100 mg) is a prescription anticancer medicine containing Oxaliplatin 100 mg, a platinum-based chemotherapy agent widely used in the treatment of colorectal cancer and other gastrointestinal malignancies. Oxaliplatin belongs to a class of medicines known as Platinum Coordination Compounds, which work by damaging the DNA of cancer cells, preventing them from growing and multiplying.
Cancer cells divide rapidly and depend on intact DNA for survival and replication. Oxaliplatin forms cross-links within DNA strands, disrupting the genetic material of cancer cells and ultimately leading to cell death. This mechanism helps slow tumor growth and supports effective cancer management.
OXALIEVA 100 MG is commonly used as part of combination chemotherapy regimens, particularly with fluoropyrimidine-based therapies such as 5-Fluorouracil (5-FU) and Leucovorin. It plays a significant role in both adjuvant and metastatic treatment settings.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
OXALIEVA 100 MG is commonly prescribed for:
Manufactured according to stringent pharmaceutical quality standards, OXALIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Oxaliplatin therapy require regular blood tests, liver and kidney function monitoring, and neurological assessments to ensure safe and effective treatment.
Due to its established efficacy in colorectal cancer management, OXALIEVA 100 MG remains an important medicine in modern oncology practice.
OXALIEVA 100 MG (Oxaliplatin Injection USP 100 mg) is primarily used in the treatment and management of certain cancers.
The medicine is widely used in the treatment of colon and rectal cancers.
Oxaliplatin helps manage cancer that has spread beyond the original site.
The medicine may be administered after surgery to reduce the risk of cancer recurrence.
Doctors may incorporate Oxaliplatin into treatment plans for selected gastrointestinal cancers.
The medicine is commonly used with fluoropyrimidine-based chemotherapy regimens.
Oxaliplatin supports disease control in advanced-stage cancers.
The medicine is part of internationally recognized cancer treatment regimens.
Oxaliplatin belongs to a class of medicines known as Platinum-Based Anticancer Agents.
OXALIEVA works by:
This mechanism helps reduce cancer spread and supports effective disease management.
Like all medicines, OXALIEVA 100 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Numbness, tingling, or sensitivity in the hands and feet is a common side effect.
Digestive discomfort may occur during treatment.
Weakness and tiredness are frequently reported.
Digestive disturbances may occur during therapy.
Reduced appetite may affect nutritional intake.
The medicine may decrease white blood cells, red blood cells, and platelets.
Inflammation or ulcers inside the mouth may develop.
Lower white blood cell counts may increase susceptibility to infections.
Patients may experience unusual sensitivity to cold temperatures or cold objects.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of OXALIEVA 100 MG (Oxaliplatin Injection USP 100 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the cancer being treated.
Dosage is generally calculated based on body surface area.
The chemotherapy regimen may influence dosing schedules.
Laboratory monitoring helps guide treatment decisions.
Kidney, liver, and bone marrow function may affect dosage planning.
Before starting treatment, inform your doctor if you have:
Patients receiving Oxaliplatin should:
Patients should also disclose all prescription medicines, vitamins, supplements, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for the treatment of colorectal cancer and selected gastrointestinal cancers.
Oxaliplatin is a platinum-based chemotherapy medicine that damages cancer cell DNA and prevents cancer growth.
Yes. Oxaliplatin is a platinum-based chemotherapy agent.
Peripheral neuropathy, including numbness and tingling in the hands and feet, is one of the most common side effects.
The medicine can affect nerves, making patients unusually sensitive to cold temperatures and cold objects.
Yes. It may reduce white blood cells, red blood cells, and platelet counts, requiring regular monitoring.
Yes. Blood tests, neurological assessments, and clinical evaluations are important throughout therapy.
Yes. This medicine should only be administered by qualified healthcare professionals experienced in oncology treatment.